OCUL Ocular Therapeutix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCUL

Price (delayed)

$8.915

Market cap

$1.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.44

Enterprise value

$1.36B

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 17
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 20

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation ...

Highlights
The equity has surged by 119% year-on-year but it has declined by 11% since the previous quarter
Ocular Therapeutix's quick ratio has increased by 46% YoY but it has decreased by 4% QoQ
The net income has dropped by 51% year-on-year and by 9% since the previous quarter
The company's EPS fell by 26% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ocutx.com
Peers: ANIK ZBH WST STE

Key stats

What are the main financial stats of OCUL

OCUL stock price

How has the Ocular Therapeutix stock price performed over time
Intraday
6.77%
1 week
-2.57%
1 month
-8.75%
1 year
6.38%
YTD
-26.57%
QTD
5.25%

Financial performance

How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$52.04M
Gross profit
$45.4M
Operating income
-$299.44M
Net income
-$290.5M
Gross margin
87.2%
Net margin
-558.2%
The net margin has plunged by 73% YoY and by 9% from the previous quarter
Ocular Therapeutix's operating margin has plunged by 68% YoY and by 11% from the previous quarter
The net income has dropped by 51% year-on-year and by 9% since the previous quarter
The operating income has contracted by 47% YoY and by 11% from the previous quarter

Price vs fundamentals

How does OCUL's price correlate with its fundamentals

Growth

What is Ocular Therapeutix's growth rate over time

Valuation

What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
3.34
P/S
38.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.2
The company's EPS fell by 26% YoY
The equity has surged by 119% year-on-year but it has declined by 11% since the previous quarter
OCUL's price to book (P/B) is 79% less than its 5-year quarterly average of 14.8 and 37% less than its last 4 quarters average of 5.0
The stock's P/S is 95% above its 5-year quarterly average of 18.4 but 2.3% below its last 4 quarters average of 36.8
The revenue has contracted by 13% YoY

Efficiency

How efficient is Ocular Therapeutix business performance
The company's return on sales has shrunk by 77% YoY and by 10% QoQ
OCUL's return on invested capital has dropped by 61% year-on-year and by 9% since the previous quarter
The return on assets has declined by 17% year-on-year but it has grown by 5% since the previous quarter
Ocular Therapeutix's return on equity has increased by 10% QoQ but it has decreased by 10% YoY

Dividends

What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUL.

Financial health

How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets has surged by 80% YoY but it has decreased by 9% QoQ
Ocular Therapeutix's quick ratio has increased by 46% YoY but it has decreased by 4% QoQ
The debt is 86% less than the equity
The equity has surged by 119% year-on-year but it has declined by 11% since the previous quarter
The company's debt to equity has shrunk by 52% YoY but it rose by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.